Voices
Amer Zeidan: First FDA Approval of a PROTAC Therapy Based on Craig Crews Lab Discoveries
Amer Zeidan and Craig Crews

Amer Zeidan: First FDA Approval of a PROTAC Therapy Based on Craig Crews Lab Discoveries

Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on X:

“First ever PROTAC FDA approval based on Yale Cancer Center, Dr Craig Crews lab discoveries for ER+ve metastatic breast cancer (Dr Crews work also led to approval of carfilzomib for MMsm approval in 2012)”

Other articles featuring Amer Zeidan on OncoDaily.

Amer Zeidan Breast Cancer cancer Craig Crews FDA OncoDaily Oncology